Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.925
−$0.015 · -0.77%
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Regular session
$1.925
−$0.015 · -0.77%
Regular session · ET · Market data may be delayed.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Day range
Current $1.925
52-week range
Current $1.925
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
38
Expensive
Sentiment
60
Mixed
Risk
38
Moderate Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Day range
Current $1.925
52-week range
Current $1.925
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 260.5K USD | 123.44K USD | 3.1M USD |
| Cost of goods sold | — | 26.27K USD | 13.62M USD | 6.72K USD | 11.36M USD |
| Gross profit | — | −26.27K USD | −13.36M USD | 116.72K USD | −8.26M USD |
| Research and development | 29.79M USD | 17.21M USD | 13.62M USD | 12.03M USD | 11.36M USD |
| Selling, general, and administrative | 23.56M USD | 11.38M USD | 6.73M USD | 6.21M USD | — |
| Operating expenses | 51.97M USD | 28.56M USD | 6.73M USD | 18.25M USD | 6.51M USD |
| Interest income | 3.72M USD | 1.07M USD | 1.06M USD | 74.45K USD | 19.92K USD |
| Interest expense | — | — | — | 74.45K USD | 19.92K USD |
| Depreciation and amortization | 60.5K USD | 26.27K USD | 177.4K USD | 6.72K USD | 14.77M USD |
| Operating income | −51.97M USD | −28.59M USD | −20.09M USD | −18.13M USD | −14.77M USD |
| Net income | −48.26M USD | −27.52M USD | −19.03M USD | −18.05M USD | −14.79M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 30, 2023 | 1:6 | — | — |
Effective Jun 30, 2023
1:6
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.7M0.00%2.3T USD0.03%$379.14-0.50%
iShares Russell 2000 ETFIWM6.84M0.01%78.56B USD0.19%$277.1-0.22%
Vanguard Extended Market ETFVXF2.33M0.00%95.4B USD0.05%$232.87-0.27%
Vanguard Russell 2000 ETFVTWO1.61M0.01%18B USD0.06%$111.92-0.26%
iShares Micro-Cap ETFIWC885.1K0.07%1.33B USD0.60%$182.44-0.50%
ALPS Medical Breakthroughs ETFSBIO341.25K0.18%188.26M USD0.50%$53.835-0.54%
Vanguard Russell 2000 Value ETFVTWV260.22K0.02%1.4B USD0.06%$185.63+0.36%
Avantis U.S. Small Cap Equity ETFAVSC236.36K0.01%3.04B USD0.25%$69.84+0.30%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCALPS Medical Breakthroughs ETFSBIOVanguard Russell 2000 Value ETFVTWVAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
